.svg){kind=small}
Mar-2026
Sales
Trend
6-Month
Product Count
SKUs
Overview
Market Insights Snapshot
Canna Clinicals has demonstrated notable performance in the Tincture & Sublingual category in New York. Their ranking saw a significant improvement from December 2025 to February 2026, moving from 10th to 5th place, before slightly declining to 7th place in March 2026. This upward trajectory in February indicates a strong market presence and potential consumer preference for their products. Despite the slight dip in March, maintaining a position within the top 10 suggests a consistent demand and competitive edge in the New York market.
While Canna Clinicals has managed to climb the ranks in New York, the absence of rankings in other states or provinces indicates a potential area for growth or an existing limitation in their market penetration. The fact that they are not present in the top 30 brands in other regions could be seen as a missed opportunity to capitalize on broader market trends. However, the substantial increase in sales from January to February 2026 in New York reflects a successful strategy or product launch that could be leveraged in other markets. This data suggests that while Canna Clinicals has a strong foothold in New York, there is room for expansion and increased visibility in other regions.
Competitive Landscape
In the competitive landscape of the Tincture & Sublingual category in New York, Canna Clinicals has shown a notable fluctuation in its market position over the first quarter of 2026. Starting from a rank of 10 in December 2025, Canna Clinicals made a significant leap to rank 5 in February 2026, before settling at rank 7 in March 2026. This upward trend in February suggests a successful strategic move or product launch that temporarily boosted its market presence. In comparison, OMO - Open Minded Organics consistently maintained a strong position, ranking 5th in December and March, indicating a stable market hold. Meanwhile, High Falls Canna New York and Ithaca Organics Cannabis Co. experienced slight rank fluctuations, with High Falls maintaining a competitive edge over Ithaca Organics. The consistent presence of Harney Brothers Cannabis in the lower ranks suggests a struggle to capture a larger market share. These dynamics highlight the competitive pressure Canna Clinicals faces, emphasizing the importance of strategic agility to sustain and improve its market position.
Notable Products
In March 2026, the top-performing product for Canna Clinicals was the CBD/THC 1:10 Max Strength Tincture (100mg CBD, 1000mg THC, 30ml) in the Tincture & Sublingual category, maintaining its number one rank for four consecutive months with sales of 610 units. The CBD/THC Unwind Tincture (1050mg CBD, 90mg THC, 15ml) held steady at the second position, showcasing consistent popularity. The CBD/CBN/THC Sleep Tincture (300mg CBD, 300mg CBN, 150mg THC) remained in third place, with a slight decline in sales compared to February. The CBD/THC 1:1 Max Strength Capsules 10-Pack (100mg CBD, 100mg THC) continued to rank fourth, experiencing a notable increase in sales. A new entry, the CBD/THC Balance Tincture (100mg CBD, 500mg THC), debuted at the fifth position, indicating a positive reception among consumers.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
